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Abstract 
John Mitchell Troutman: Molecular Dosimetry of N7-Guanine Adducts in Male and Female 
Mice Exposed to 1,3-Butadiene by Inhalation 
 
(Under the direction of Dr. James A. Swenberg) 
 
1,3-Butadiene (BD) is a well-characterized carcinogen that is both an occupational and 
environmental hazard and an important industrial chemical widely used in the production of 
rubber and plastic and is also present in automobile exhaust and cigarette smoke. Upon 
metabolic activation in vivo, it forms three epoxides that can react with nucleophilic sites in 
biomolecules:  1,2,3,4-diepoxybutane (DEB), 1,2-epoxy-3-butene (EB), and  3,4-epoxy-1,2-
butane-diol (EBD).  We characterized the molecular dosimetry of N-7 guanine adduct 
formation by these metabolites of BD in the liver of male and female B6C3F1 mice exposed 
to varying concentrations of BD. The adducts, racemic and meso forms of N-7-(2,3,4-
trihydroxy-3-buten-2-yl)guanine (THB-Gua), N-7-(2-hydroxy-3-buten-1-yl)guanine (HB-
Gua I), and N-7-(1-hydroxy-3-buten-2-yl)guanine (HB-Gua II) were similar in male and 
female B6C3F1 mice at all levels where liver tissue was available for both sexes.  Thus, no 
gender differences in adduct formation were noted.  The THB-Gua adducts were the most 
abundant and exhibited a supralinear dose response.   
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To my family and all my pets (past and present): to err is human, to forgive feline. In 
memoriam of my cat named “fish” who will always have a special place in my heart and 
mind. Lastly, I shall end this dedication with my favorite quote from Rudolf Virchow: 
“Between animal and human medicine there is no dividing line—nor should there be. The 
object is different but the experience obtained constitutes the basis of all medicine.”
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Chapter 1 
Introduction 
1,3-Butadiene (BD) is a petrochemical widely used in the production of synthetic 
rubber and plastic (1). It is also an environmental toxin found in automobile exhaust, fossil 
fuels, and in cigarette smoke (2;3). Recently, BD has been rated the cigarette constituent with 
the highest cancer risk index (4).  BD is classified by the USEPA and IARC as a human 
carcinogen based on human epidemiologic studies and laboratory animal data (5;6).  Human 
epidemiologic studies have shown an increased incidence of leukemia in workers exposed to 
BD in synthetic rubber production and an increase in lymphohematopoietic cancers in BD 
production workers that were not exposure related (6-10) . Long term inhalation exposure of 
mice and rats to BD caused the development of tumors at multiple sites (11-13), with mice 
developing cancer at exposures 160 times lower than rats and therefore being a much more 
sensitive species than rats (6).  The complexity of BD carcinogenesis has been attributed 
mainly to species-dependent differences in BD metabolism.  
Bioactivation of BD in animal and human tissues to yield reactive epoxides is an 
important determinant of the mutagenic and carcinogenic effects of BD (14).  Upon 
metabolic activation, BD is first oxidized to 3,4-epoxy-1-butene (EB), which can be further 
oxidized  to 1,2,3,4-diepoxybutane (DEB) or can be metabolized by epoxide hydrolase (EH) 
to form 1-butene-3,4-diol (Scheme 1), which can be further metabolized to 3,4-epoxy-1,2-
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butanediol (EBD) (15-19).  The three epoxide metabolites of BD (EB, DEB, and EBD) are 
reactive electrophiles capable of binding to nucleophilic sites within biomolecules such as 
Scheme 1. Metabolism of BD to DNA-Reactive Epoxides
 
proteins and DNA to form covalent adducts (20;21) (Figure 1). Both EB and DEB are direct-
acting mutagens, which are believed to play important roles in the 
mutagenicity/carcinogenicity of BD. However, BD derived metabolites differ in their 
mutagenic potency up to 200 fold with DEB being the most mutagenic metabolite (22-27). 
Thus, DEB is considered the most carcinogenic metabolite of BD because of its potent 
genotoxicity and its ability to form bifunctional DNA adducts such as exocyclic DNA lesions 
and DNA-DNA cross-links (24;28-30) .  DEB preferentially alkylates the N-7 position of 
guanine bases in DNA to form N-7-(2-hydroxy-3,4-epoxybut-1-yl)-guanine (N-7-HEB-dG) 
adducts (30;31).   The epoxide group of N-7-HEB-dG can then be hydrolyzed to N-7-(2,3,4-
trihydroxybut-1-yl)-guanine (THB-G) (28;30).  The formation of pro-mutagenic DNA 
adducts define the causal link between exposure and tumor development (32). 
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Multiple BD mouse studies have revealed gender differences in the development of 
neoplasia, Hprt mutant frequencies (MFs), and amounts of DNA adducts formed (26;27;30).  
Inhalation studies in mice revealed pronounced gender differences in sensitivity toward Hprt 
mutant frequencies (MFs) in BD exposed male and female B6C3F1 mice.  Female mice 
exposed to 1250 ppm BD for 2 weeks demonstrated a 2.3 fold greater number of MFs than 
male mice (26)(Figure 2). In addition, chronic BD inhalation studies in B6C3F1 mice 
demonstrated male and female mice had tumors of similar tissues, but for the most part, 
females developed tumors at lower exposure concentrations.  For example, lung and liver 
tumors in female mice were observed at exposure concentrations of 6.25 and 20 ppm BD, 
respectively.  By comparison, the respective exposure concentrations of BD that produced 
Figure  1: Formation of N 7-guanine adducts. Shown are N 7- HB-Gua, 
bis N 7- Gua-BD-diol and THB- Gua.
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lung and liver tumors in male mice were 62.5 and 200 ppm (33) which represents a 10 fold 
increase in concentration.  There are also gender differences in the formation of bis-N7G-BD 
adduct (a DEB-specific DNA adduct) in male and female B6C3F1 mice exposed to 625 and 
200 ppm BD for two weeks.  Bis-N7G-BD adduct amounts in female mice are 2- to 2.5- fold 
higher than in male mice (30).  Some studies have attributed this gender difference in 
neoplasia, MFs, and amount of adduct formed to differences in BD metabolism, especially of 
DEB.  However, a recent study of the DEB specific hemoglobin adduct N,N-(2,3-dihydroxy-
1,4-butadiyl)valine (pyr-Val) in mice and rats showed no significant gender differences at the 
exposure concentrations and durations studied (34) .  This study would indicate that there is 
no difference in metabolism of BD and more specifically the highly mutagenic DEB 
metabolite in female and male rodents at multiple exposure concentrations and durations.  An 
alternative explanation for the multiple gender differences noted above would be a variation 
in DNA repair pathways for mice and, to a lesser extent, rats.  The DNA repair pathway most 
often linked with BD, and more specifically DEB-induced genotoxic insults is the Fanconi 
Anemia pathway.  The ability of DEB to form DNA interstrand crosslinks is often used as a 
cellular marker for the diagnosis of Fanconi Anemia disease in suspect non-clinical patients 
(35).  Fanconi anemia (FA) is an inherited genomic instability disorder caused by mutations 
in genes regulating replication-dependent removal of interstrand DNA crosslinks.  The 
Fanconi Anemia pathway is thought to coordinate a complex mechanism that enlists three 
classic DNA repair pathways which include homologous recombination, nucleotide excision 
repair, and mutagenic translesion synthesis (36). Interstrand DNA−DNA adducts are among 
the most toxic nucleobase lesions because they inhibit DNA replication and transcription, 
and their enzymatic removal in cells is problematic because of the loss of template 
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information in both DNA strands.  This requires a complex repair process usually involving 
both nucleotide excision repair and recombination repair, which can lead to DNA 
rearrangements and deletions (37). Thus, the Fanconi Anemia pathway would be a leading 
candidate to investigate as the cause of the gender differences in MFs, specific adduct levels, 
and neoplasm development at differing exposures of BD.  
 In this study, the molecular dosimetry of DNA adduct formation by BD has been 
investigated in liver of male and female B6C3F1 mice exposed to 0, 0.1, 0.5, 1.5, 200, or 625 
ppm BD by inhalation for 2 weeks and additionally in the liver of female B6C3F1 mice 
exposed to 0, 1.0, 6.25, or 62.5 BD by inhalation for 2 weeks.  We have developed a 
quantitative high-performance liquid chromatography (HPLC)-electrospray ionization (ESI)-
tandem mass spectrometry (MS/MS) methodology for two types of BD induced DNA 
adducts, N-7-(2,3,4-trihydroxy-3-buten-2-yl)guanine (THB-G, racemic and meso) and N-7-
(2-hydroxy-3-buten-1-yl)guanine (HB-G I), and N-7-(1-hydroxy-3-buten-2-yl)guanine (HB-
G II). In our approach, the DNA adducts are released from the DNA backbone by neutral 
thermal hydrolysis, enriched by ultrafiltration and HPLC, and analyzed by either 
LC/ESI+/MS/MS or nano-LC/ESI+/MS/MS depending upon the exposure, using the [15N5]-
labeled adducts as internal standards (38). THB-G and HB-G I and II adducts were chosen 
for evaluation because the THB-G adducts are formed in much greater amounts compared to 
other adducts such as the interstrand DNA-DNA cross-links adducts and HB-G.  However, 
even though these N-7 guanine adducts are frequently formed, they have minimal biological 
relevance since they are chemically unstable and do not participate in Watson-Crick base 
pairing (39). Nevertheless, it is important to have detailed knowledge of the internal 
formation of each potentially mutagenic metabolite and its dependence on species, gender, 
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and exposure concentrations. We report herein a comprehensive exposure-response of N-7 
guanine adduct formation observed in the livers of male and female mice that had been 
exposed to various concentrations of BD by inhalation and the impact of gender on 
quantification of THB-G and HB-G adducts.  Furthermore, we expanded the range of 
exposure that these N-7 guanine adducts can be accurately measured from a previous low of 
20 ppm to 0.5 ppm for THB-G and 62.5 ppm to 6.25 ppm for HB-G using either 
LC/ESI+/MS/MS or nano-LC/ESI+/MS/MS and greatly lowered the amount of DNA needed 
for such quantification from 1000 µg to 50 µg for high level exposures and to 300 µg for low 
level exposure.  The majority of this credit for improvement can be given to more sensitive 
instrumentation and, to a lesser extent, HPLC enrichment of the adducts.
  
 
Chapter 2 
Materials and Methods 
Animals and Treatment 
 BD inhalation exposures were performed at the Lovelace Respiratory Research 
Institute (Albuquerque, NM) as previously reported (30).  Male and female B6C3F1 mice 
were randomly separated into air-control and exposure groups by weight and were housed 
individually in hanging wire stainless-steel cages according to NIH guidelines (NIH 
Publication 86-23; 1985).  All procedures involving the use of animals were approved by the 
Institutional Animal Care and Use Committee.  Experimental mice were exposed using 
multitiered whole-body exposure chambers (H-2000, Laboratory Products).  Mice in one 
chamber received filtered air only as a control group, and mice in the other chamber received 
nominal 0.1, 0.5, 1.0, 1.5, 6.25, 62.5, 200, or 625 ppm BD for 2 weeks (6 h/d, 5 d/wk). Mice 
were housed within exposure chambers throughout the experiment and had free access to 
food and water except for removal of food during the 6-h exposure periods.  Within 2 h after 
cessation of the final day of exposure, mice were euthanized via cardiac puncture, and tissues 
were harvested and snap-frozen for storage at – 80 ˚C.  Tissues were shipped on dry ice to 
the University of North Carolina at Chapel Hill where they were stored at – 80 ˚C until DNA 
extraction.  
Chemicals  
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 BD (>99%) was acquired from Aldrich Chemical Co. (St. Louis, MO).  [15N5]THB-G 
internal standard and THB-G analyte standard were gifts from Dr. Natalia Tretyakova 
(University of Minnesota, Minneapolis, MN). [15N5]HB-G I and [15N5]HB-G II internal 
standards and HB-G I and HB-G II analyte standards were synthesized by the Department of 
Environmental Sciences and Engineering at the University of North Carolina at Chapel Hill 
as previously described (20;31;40). Nucleic acid purification grade lysis buffer, protein 
precipitation solution and proteinase K were purchased from Qiagen (Valencia, CA).  All 
other reagents and solvents were purchased from Fisher Scientific. 
DNA Isolation 
 DNA isolation was performed with modification to the Puregene DNA extraction kit 
(Qiagen, Valencia, CA) as described previously (41). All procedures were performed on ice. 
Briefly, frozen liver tissue (300-400 mg) was thawed at 4 °C and homogenized in 3 mL Lysis 
Solution with a Tehran homogenizer (Wheaton Instruments, Millville, NJ). Following 
centrifugation, nuclear pellets from homogenates were incubated with a mixture of RNase T1 
and RNase A for 30 min at 37 °C, then overnight at 4°C with proteinase K (50 U; Applied 
Biosystems, Foster City, CA). Protein was precipitated with Protein Precipitation Solution 
and centrifugation at 2000 × g for 10 min. The supernatant containing the DNA was 
transferred to a clean 15 mL tube and precipitated by mixing with 6 mL isopropanol and 
subsequent centrifugation at 2000 × g for 5 min at 4 °C. The DNA pellet was washed with 6 
mL 70% ethanol, centrifuged at 2000 × g for 1 minute at 4 °C, air dried, and resuspended in 
sterilized double distilled water. DNA purity and amounts were determined by UV 
spectrophotometry (Shimadzu model UV160U).  All A260/A280 ratios were between 1.7 and 
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1.9, ensuring minimal protein contamination and there was no need for DNA reisolation.  
The DNA solution was stored at -80°C until assayed.  
DNA Hydrolysis 
 Either 50 (for 625 and 200 ppm), 100 (for 62.5 ppm), or 300 (for 6.25, 1.5, 1.0, 0.5, 
0.1 and 0 ppm) µg of DNA (depending on exposure level) was used, based on UV 
measurements, spiked with internal standards, [15N5]THB-G (racemic), [15N5]HB-G I, and 
[15N5]HB-G II and diluted to 300 µL with HPLC-grade water.  The spiked DNA samples 
were subjected to neutral thermal hydrolysis at 95 ˚C for 30 minutes.  Immediately after 
incubation samples were cooled on ice. The hydrolysates containing the adducts were 
separated from the DNA backbone by Centricon-10 filtration at 13,500 rpm, 4 ˚C for 45 
minutes.  After the filtrate was separated, an additional 100 µL HPLC-grade water was added 
to the retentate to wash the DNA backbone (13,500 rpm, 4 ˚C, 45 minutes) and both filtrates 
were combined.   
High Performance Liquid Chromatography (HPLC)   
The samples of hydrolyzed DNA were purified on an Agilent 1200 series HPLC 
system equipped with a diode-array detector (Santa Clara, CA) and automated fraction 
collector to separate N-7 guanine adducts from matrix. Separation was performed on a 
SunFire C18 4.6 × 250 mm 5 µm column (Milford, MA) using a gradient of 10mM 
ammonium formate (A) in water (adjusted to pH 4.3 with formic acid) and methanol (B).  A 
linear gradient was run from 15% methanol to 30% methanol from 0 to 20 minutes.  The 
flow rate was 1mL/min and the UV absorbance was monitored at 254 nm. Methanol 
composition was increased linearly to 80% in 2 min; then held at 80% for 6 min, then 
decreased linearly to 30% in 2 min, then decreased linearly to 15% in 1 min, and held at 15% 
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for 9 min for column re-equilibration.  A 400 µL aliquot of sample was injected.  The column 
oven, autosampler tray and fraction collector chamber temperatures were maintained at 30 °C, 
4 °C and 4 °C, respectively.  The retention times of THB-G, HB-G I, and HB-G II were ~ 6.5 
min, 17 min, and 19 min respectively.  Fractions containing the N-7 guanine adducts were 
automatically collected from 1.5 min before until 1.5 min after its predicted retention time.  
The fraction collection tubes were placed in a SpeedVac concentrator (ThermoFinnigan, San 
Jose, CA) and evaporated to dryness.  Sample residue was transferred to autosampler vials 
via 2 x 130 µL washings with 50:50 water:methanol (vol/vol), evaporated to dryness in a 
SpeedVac concentrator, and finally redissolved in 20 µL HPLC grade water for subsequent 
analysis by LC-MS/MS.   
Quantitation by HPLC-nanoESI+-MS/MS 
The quantitative analysis of HB-G I and HB-G II (exposures of 0, 0.1, 0.5, 1.0, 1.5, 
6.25, or 62.5 ppm BD)  was performed with a nanoAcquity UPLC (Waters, Milford, MA) 
coupled to a TSQ-Quantum Ultra triple-quadrupole mass analyzer (ThermoFinnigan, San 
Jose, CA) using the nanospray source in positive mode.  The trap column was a Waters 180 
µm x 20 mm Symmetry C18 5 µm, and separation was performed on a 100 µm × 100 mm 
HSS T3 C18 1.8 µm column (Waters, Milford MA). The mobile phase consisted of 0.1% 
acetic acid in water and acetonitrile.    Samples were kept at 4 ˚C during analysis. The sample 
was first injected onto the trap column at a flow rate of 10 µL per min for 1.5 min at an initial 
methanol concentration of 5%, then flow was directed in-line with the analytical column.  
Gradient elution was performed at a flow rate of 600 nL per min.  The methanol composition 
started at 5% and increased linearly to 80% in 10 min, was held at 80% for 2 min, decreased 
to 5% in 2 min, then held at 5% for 6 min for column re-equilibration.  The retention time of 
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HB-G I and HB-G II was 7.6 min (unable to separate the two isomers), and the total run time 
was 20 min.  The analyte and internal standards were detected in selected reaction 
monitoring mode (SRM), monitoring the transitions of m/z 222.1 → 152.1 (collision energy 
15 eV) for HB-G I and II (analyte) and m/z 227.1 → 157.1 (collision energy 35 eV) for 
[15N5]HB-G I and II (internal standard).  Other nano-electrospray conditions were as follows: 
positive mode, spray voltage of 2000 V, capillary temperature of 280˚C.  The amount of 
adduct in each sample was calculated from the ratio of the analyte and internal standard peak 
areas.   
Quantitation by HPLC-ESI+-MS/MS 
 The quantitative analysis of THB-G (all levels of exposure), HB-G I and II (only 
higher levels of exposure, 200 and 625 ppm BD) was performed with an Acquity UPLC 
(Waters, Milford, MA) coupled to a TSQ-Quantum Ultra triple-quadrupole mass analyzer 
(ThermoFinnigan) using heat assisted electrospray ionization (HESI) in positive mode.  
Samples were kept at 4 ˚C during analysis.  Separation was performed on a 2.1 × 100 mm 
HSS T3 C18, 1.8 µm column (Waters, Milford MA) with gradient elution at a flow rate of 
200 µL per min using 0.1% acetic acid in water and methanol.  Methanol composition started 
at 1% and increased linearly to 5% B in 2 min, was held at 5% for 8 min, increased linearly 
to 80% in 2 min, held at 80% for 2 min, decreased to 1% in 1 min, then held at 1% for 4 min 
for column re-equilibration.  The retention time of THB-G was ~2.9 min, HB-G I ~7.6 min, 
HB-G II ~7.8 min, and the total run time was 20 min.  The analyte and internal standard were 
detected in Selected Reaction Monitoring (SRM), monitoring the precursor to fragment ion 
transitions of m/z 256.1 → 152.1 and m/z 261.1 → 157.1 for THB-G and [15N5]THB-G, 
respectively and m/z 222.1 → 152.1 and m/z 227.1 → 157.1 for HB-G I and II and 
 12
[15N5]HB-G I and II, respectively.  The electrospray conditions were as follows: positive 
mode, spray voltage of 3000 V, vaporizer (HESI) temperature of 250°C, sheath gas flow rate 
35 (arbitrary units), auxiliary gas flow rate 30 (arbitrary units), capillary temperature of 
285°C, and collision energy of 12 eV.  The amount of adduct in each sample was calculated 
from the ratio of the analyte and internal standard peak areas.   
Method validation  
 Method validation was performed  by analyzing the analyte standards three times on 
the same day and on three different days to obtain intraday and interday precision.  The 
intraday and interday precision was defined as the relative standard deviation (RSD) and 
accuracy was determined by calculating the relative error (RE).  Three replicates of control 
calf thymus DNA (100 µg) were added to HB-G I (5 and 10 µM), or HB-G II (5 and 10 µM), 
or THB-G (25 and 50 µM) and their corresponding internal standards (100 µM). The 
validation samples were processed (by neutral thermal hydrolysis, filtration, and fraction 
collection (HPLC clean-up)) following the same methods as real samples. The intraday 
precision was determined within one day by analyzing three replicate control samples at 
concentrations of 5 and 10 µM for HB-G I and II on the HPLC-ESI+-MS/MS and HPLC-
nanoESI+-MS/MS and at concentrations of 25 and 50 µM for THB-G on the HPLC-ESI+-
MS/MS.  The interday precision was determined on three separate days for the control 
samples.   
Statistical Analysis 
 Statistical analyses were performed using Microsoft Excel spreadsheet analysis tools.  
A Student’s t test was used to determine the P values for female/male differences in adduct 
levels. 
  
 
Chapter 3 
Results 
Method Validation 
 The interday and intraday precision and accuracy of the analytical method are listed 
in Table 1.  The RSD of both interday and intraday for HB-G I and HB-G II on the HPLC-
nanoESI+-MS/MS were below 6.4%.  The accuracies calculated as relative error were within 
the range of -4.8 to 0.6%.  The RSD of both interday and intraday for HB-G I and HB-G II 
on the HPLC-ESI+-MS/MS were below 8.71%.  The accuracies calculated as relative error 
were within the range of -5.8 to 1.8%.  The RSD of both interday and intraday for THB-G on 
the HPLC-ESI+-MS/MS were below 9.06%.  The accuracies calculated as relative error were 
within the range of -10.8 to -5.0%.  For the HPLC-ESI+-MS/MS, the limit of detection 
(LOD) with a signal-to-noise of >2 was 3 fmol THB-G standard per injection; therefore, the 
limit of quantitation (LOQ) was set to be three times the LOD (9 fmol of THB-G per 
injection) with a signal-to-noise of > 6.  The LOD with a signal-to-noise of >2 was 1 fmol 
HB-G I and HB-G II standard per injection; therefore, the LOQ was set to be three times the 
LOD (3 fmol of HB-G I and HB-G II per injection) with a signal-to-noise of > 6.  For the 
HPLC-nanoESI+-MS/MS, the LOD with a signal-to-noise of >2 was 500 amol HB-G I and 
HB-G II standard per injection; therefore, the LOQ was set to be three times the LOD (1.5 
fmol of HB-G I and HB-G II per injection) with a signal-to-noise of > 6.  The lower detection 
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limit for HB-G adducts compared to that for THB-G adducts was attributed to a higher 
sensitivity of ESI+/MS/MS detection for HB-G adducts. 
Adduct
Concentration 
(uM)
Precision 
(%RSD)
Accuracy 
(%RE)
Concentration 
(uM)
Precision 
(%RSD)
Accuracy 
(%RE)
10.0 1.73 -1.9 10.0 2.14 -2.1
5.00 5.96 0.6 5.00 6.4 -3.2
Adduct
Concentration 
(uM)
Precision 
(%RSD)
Accuracy 
(%RE)
Concentration 
(uM)
Precision 
(%RSD)
Accuracy 
(%RE)
10.0 1.51 -1.1 10.0 2.48 -3.5
5.00 4.40 0.0 5.00 5.88 -4.8
Adduct
Concentration 
(uM)
Precision 
(%RSD)
Accuracy 
(%RE)
Concentration 
(uM)
Precision 
(%RSD)
Accuracy 
(%RE)
10.0 1.21 -1.1 10.0 3.8 -2.7
5.00 4.91 1.8 5.00 8.7 -5.8
Adduct
Concentration 
(uM)
Precision 
(%RSD)
Accuracy 
(%RE)
Concentration 
(uM)
Precision 
(%RSD)
Accuracy 
(%RE)
10.0 1.42 -1.8 10.0 4.49 -2.0
5.00 3.89 -2.4 5.00 8.71 -3.6
Adduct
Concentration 
(uM)
Precision 
(%RSD)
Accuracy 
(%RE)
Concentration 
(uM)
Precision 
(%RSD)
Accuracy 
(%RE)
50.0 3.84 -6.4 50.0 4.92 -5.0
25.00 5.85 -6.5 25.00 9.06 -10.8
HPLC-nanoESI+-MS/MS
HPLC-ESI+-MS/MS 
HB-G I
HB-G II
HB-G I
HB-G II
THB-G
Determined 
concentration (uM) 
9.81 ± 0.17
5.03 ± 0.30
Intraday (n=3) Interday (n=3)
Determined 
concentration (uM) 
9.79 ± 0.21
4.84 ± 0.31
Intraday (n=3) Interday (n=3)
Determined 
concentration (uM) 
Determined 
concentration (uM) 
9.96 ± 0.15 9.65 ± 0.24
5.00 ± 0.22 4.76 ± 0.28
Intraday (n=3) Interday (n=3)
23.38 ± 1.37 22.29 ± 2.02
Determined 
concentration (uM) 
Determined 
concentration (uM) 
9.77 ± 0.12 9.73 ± 0.37
5.09 ± 0.25 4.71 ± 0.41
46.81 ± 1.77 47.52 ± 2.34
Intraday (n=3) Interday (n=3)
Determined 
concentration (uM) 
Determined 
concentration (uM) 
9.82 ± 0.14 9.80 ± 0.44
4.88 ± 0.19 4.82 ± 0.42
Intraday (n=3) Interday (n=3)
Determined 
concentration (uM) 
Determined 
concentration (uM) 
 
Table 1: Intraday and interday accuracy and precision 
 [15N5]THB-G (racemic) was used as the internal standard for both the racemic and 
meso THB-Gua (44).  The response was linear for both THB-Gua and HB-Gua adducts over 
the working range (5-100 fmol injected) with R2 values of ≥0.997. Typical 5-point calibration 
curves for HB-Gua II and THB-Gua are given in Figures 3 and 4 respectively. A typical set 
of product ion chromatograms of the adducts and their internal standards is given in Figure 5 
for THB-G and HB-G I and HB-G II on the HPLC-ESI+-MS/MS and Figure 6 for HB-G on 
the HPLC-nanoESI+-MS/MS. 
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Figure 3: Calibration Curve for HB-G II 
R² = 0.9973
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0 20 40 60 80 100 120
Re
sp
o
n
se
 
Ra
tio
Concentration [fmol]
THB-Gua
 
Figure 4: Calibration Curve for THB-G 
 16
 
 
RT: 1.96 - 8.48 SM: 5G
2 3 4 5 6 7 8
Time (min)
0
10
20
30
40
50
60
70
80
90
100
R
el
at
iv
e 
Ab
u
n
da
n
ce
0
10
20
30
40
50
60
70
80
90
100
R
el
at
iv
e 
Ab
u
n
da
n
ce
RT: 2.92
AA: 1000279
RT: 3.02
AA: 916981
RT: 3.30
AA: 3069
RT: 6.37
AA: 882
RT: 7.51
AA: 722
RT: 4.00
AA: 534
RT: 8.25
AA: 815
RT: 2.38
AA: 433
RT: 4.79
AA: 389
RT: 5.49
AA: 504
RT: 2.91
AA: 339568
RT: 3.14
AA: 27150 RT: 8.22
AA: 1380
RT: 3.94
AA: 5592
RT: 4.88
AA: 525
RT: 5.58
AA: 488
RT: 7.18
AA: 681
NL: 2.80E5
TIC F: + c ESI SRM 
ms2 
256.100@cid20.00 
[151.600-152.600]  
MS  ICIS 
THB-HB_121109_044
NL: 8.62E4
TIC F: + c ESI SRM 
ms2 
261.100@cid20.00 
[156.600-157.600]  
MS  ICIS 
THB-HB_121109_044
RT: 1.96 - 8.48 SM: 5G
2 3 4 5 6 7 8
Time (min)
0
10
20
30
40
50
60
70
80
90
100
Re
la
tiv
e 
Ab
u
n
da
n
ce
0
10
20
30
40
50
60
70
80
90
100
R
el
a
tiv
e
 
Ab
u
n
da
n
ce
RT: 7.65
AA: 125276
RT: 7.94
AA: 102160
RT: 3.52
AA: 545
RT: 5.83
AA: 390
RT: 7.55
AA: 386
RT: 5.29
AA: 272
RT: 3.13
AA: 151
RT: 2.45
AA: 143
RT: 7.93
AA: 136767
RT: 7.65
AA: 116787
RT: 6.28
AA: 730
RT: 7.34
AA: 582
RT: 4.70
AA: 385
RT: 2.55
AA: 365
RT: 5.75
AA: 315
RT: 3.50
AA: 300
RT: 3.84
AA: 299
NL: 3.77E4
TIC F: + c ESI SRM 
ms2 
222.100@cid20.00 
[151.600-152.600]  
MS  ICIS 
THB-HB_121109_085
NL: 4.19E4
TIC F: + c ESI SRM 
ms2 
227.100@cid20.00 
[156.600-157.600]  
MS  ICIS 
THB-HB_121109_085
Racemic
Meso
THB-G m/z 256152
Racemic
THB-G (IS) m/z 261157
HB-G (IS)
HB-G
m/z 227157
I II
III
m/z 222152
R
e
la
ti
ve
A
b
u
n
d
a
n
c
e
R
e
la
ti
ve
A
b
u
n
d
a
n
ce
R
e
la
ti
ve
A
b
u
n
d
a
n
c
e
R
e
la
ti
ve
A
b
u
n
d
a
n
ce
 
Figure 5: Chromatogram of 625 ppm THB-G and HB-G I & II Adducts 
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Figure 6: Chromatogram of 6.25 ppm HB-G adduct
 
 
 
Molecular Dosimetry of THB-Gua and HB-Gua Adducts   
Table 2 shows the number of HB-G and THB-G adducts per 108 unmodified guanine 
bases in liver from mice exposed by inhalation to 0, 0.1, 0.5, 1.0, 1.5, 6.25, 62.5, 200, and 
625 ppm BD for 2 weeks. Both female and male B6C3F1 mice exhibited a supralinear dose 
response in the formation of THB-G and a linear dose response in the formation of HB-G 
adducts (Figures 7, 8, and 9).   Figures 7 and 8 illustrates the exposure-response data for 
THB-G DNA adducts in male and female mice.  The dose response curves for THB-G in 
both genders are supralinear, providing evidence for partial saturation of metabolic activation 
pathways in mice at exposures to >200 ppm BD.  The THB-G adducts were detectable down 
 18
to a level of 0.5 ppm due to their greater extent of formation.  Figure 9 illustrates the 
exposure-response data for HB-G DNA adducts in male and female mice.  In contrast to 
THB-G, the dose response curves are curvilinear and do not show any signs of metabolic 
saturation.  The amounts of HB-G adducts were approximately 10-20 fold lower than THB-G 
adducts.  Detection was usually at or slightly above the LOD for HB-G in samples from the 
6.25 ppm exposure group because of their presence in very low amounts.  Overall, there was 
no statistically significant gender difference (p < 0.05) in the number of adducts at exposures 
where both male and female mice were analyzed (See Figures 10 – 15).   The amounts of 
THB-G adducts were always higher than those of HB-G adducts in liver tissue.   
 
 
 
 
 
 
 
 
 
 
 
Table 2: Amounts of BD-induced N-7 guanine adducts in female and male 
B6C3F1 mice 
 
n n n n
0 14 10 14 10
0.1 8 8 8 8
0.5 8 5 8 5
1 0 5 0 5
1.5 9 6 9 6
6.25 0 5 0 5
62.5 0 5 0 5
200 11 8 11 8
625 8 5 8 5
Dose Males
HB Gua
ND
ND
ND
N/A
29 ± 11
138 ± 12
ND
N/A
N/A
122 ± 20
N/A
3914 ± 682
659 ± 85
Females
ND
ND
ND
ND
ND
8.3 ± 4.9
732 ± 150
3635 ± 353
728 ± 94
Males
ND
ND
9.56 ± 1.52
N/A
35.3 ± 6.65
N/A
6103 ± 1140
THB-Gua
6205 ± 824
Females
ND
ND
8.34 ± 1.54
17.1 ± 1.6
31.6 ± 3.64
70.1 ± 8.7
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Figure 7: Exposure-response relationship of the formation of THBG in liver; 
Female mice were denoted by a solid black line and male mice were denoted by 
a dashed black line. 
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Figure 8: Exposure-response relationship of the formation of THBG in liver 
from exposure levels of 0.5 ppm to 6.25 ppm butadiene; Female mice were 
denoted by a solid black line and male mice were denoted by a dashed black 
line. 
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Figure 9: Exposure-response relationship of the formation of HBG in liver; 
Female mice were denoted by a solid black line and male mice were denoted by 
a dashed black line. 
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Figure 10: Comparison of Butadiene induced THB-G adducts in female and 
male B6C3F1 mice at exposure concentration of 0.5 ppm 1,3-butadiene 
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Figure 11: Comparison of Butadiene induced THB-G adducts in female and 
male B6C3F1 mice at exposure concentration of 1.5 ppm 1,3-butadiene 
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Figure 12: Comparison of Butadiene induced THB-G adducts in female and 
male B6C3F1 mice at exposure concentration of 200 ppm 1,3-butadiene  
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Figure 13: Comparison of Butadiene induced THB-G adducts in female and 
male B6C3F1 mice at exposure concentration of 625 ppm 1,3-butadiene 
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Figure 14: Comparison of Butadiene induced HB-G adducts in female and male 
B6C3F1 mice at exposure concentration of 200 ppm 1,3-butadiene. 
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Figure 15: Comparison of Butadiene induced HB-G adducts in female and male 
B6C3F1 mice at exposure concentration of 625 ppm 1,3-butadiene. 
  
 
Chapter 4 
Discussion 
  The main purpose of this work was to study the molecular dosimetry of the N-7 
guanine adducts of BD to determine any gender differences in mice. The quantitation method 
used in this study is highly specific and reliable for the quantitation of N-7 guanine adducts 
because of the following: (i) the neutral thermal hydrolysis process allowed selective 
depurination of the N-7 guanine adducts, compared to guanine. (ii) Other sources of 
interference (i.e., guanine and adenine) were removed by HPLC fraction collection.  (iii) The 
MS/MS detection allowed specific identification of the product ions originating from the 
protonated adducts.  (iv)  Finally, the use of internal standards corrected for losses in sample 
processing starting with hydrolysis of DNA.  The method has good sensitivity; however, 
detection of HB-G was challenging at low BD exposures due to the presence of these adducts 
in very small amounts, rather than to a lack of sensitivity in the method.   
 This study is the first report of the relationships between exposure and the molecular 
dose of THB-G and HB-G adducts in female and male mice.  There were no gender 
differences in the amounts of adduct formed at levels of exposure where data was available 
for both sexes.  This data is in agreement with the study by Georgieva et al., (34) where the 
DEB-specific hemoglobin adduct (pyr-Val) also showed no gender differences in male and 
female mice and rats.  Taken together, these results confirm that BD metabolism in male and 
female mice is comparable.  The similarity in the amounts of N-7 guanine adducts among 
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male and female mice would not be expected on the basis of previous reports of BD 
carcinogenicity, MFs, and other DNA adducts (6;30;42).  However, no gender differences 
were found in globin adducts of the three epoxides (43).The lowest level that THB-G adducts 
were quantifiable was 0.5 ppm butadiene for 2 weeks.  The lowest level that HB-G adducts 
were quantifiable was 6.25 ppm butadiene for 2 weeks.   While these N7-guanine adducts are 
frequently formed, they have minimal biological relevance due to their chemical instability 
and their inability to interfere with Watson Crick base pairings (39).  The majority of N7-
guanine adducts are hydrolytically unstable, as N-7 alkylation of guanine produces a positive 
charge on the modified nucleobase and destabilizes the β-glycosidic bond, leading to 
spontaneous depurination and formation of abasic sites.  Even though N7-guanine adducts 
undergo spontaneous depurination resulting in apurinic sites (a potential source of mutation), 
these are efficiently repaired, so that they do not cause any increase over the endogenous 
number of AP sites (44).  Consequently, it is highly unlikely that THB-G and HB-G adducts 
are the cause of the mutations seen in BD-induced carcinogenesis.  Furthermore, since 
gender based data suggests that bis-N7G-BD is the primary adduct initiating mutagenesis and 
carcinogenesis, and does show a sex linked increase in females;  THB-G and HB-G can be 
eliminated as playing a significant role in genotoxicity, mutagenesis, and rodent 
carcinogenesis.  Nevertheless, the significance of this study demonstrates that there were no 
gender differences in the amounts of THB-G and HB-G adducts formed at exposures where 
data was available for both sexes.  Consequently, there is no gender difference in BD 
metabolism.  
Because of the similarity in the numbers of adducts, the exposure−response curves 
were also similar for male and female mice. The nonlinear response for THB-Gua in both 
 27
mice genders suggests partial saturation of metabolic activation starting at 200 ppm. The HB-
Gua adducts, on the other hand, appeared to have linear exposure−response relationships, 
although it was harder to make this conclusion because of relatively high standard deviations 
for HB-G adduct values at low levels of exposure.  The fact that THB-G adduct formation  
exhibits partial saturation at 200 ppm, but HB-G continues to increase linearly, suggests that 
the primary source of THB-G is EBD that was primarily converted from BD-diol. 
This research has demonstrated an important similarity and no differences between 
DNA adducts and BD metabolites in male and female mice. It also raises an important 
question related to BD carcinogenicity. If metabolism of BD in male and female mice is the 
same, what explains the gender differences seen in MFs, specific DEB induced DNA adducts, 
and lower levels of BD needed to induce neoplasia in female mice compared to male mice? 
Pyr-Val data and the HB-G and THB-G adduct data from this paper indicate that there is no 
difference in BD metabolism in female and male mice at multiple exposure concentrations 
and durations.  This comprehensive data set strongly suggests that a deficiency in DNA 
cross-link repair in females is the most plausible hypothesis for the gender differences in 
mutagenic and carcinogenic susceptibility.  Although not investigated in the present work, 
the Fanconi Anemia pathway, while complicated, represents possible targets for the gender-
specific repair pathway responsible for these discrepancies. FA cells have been shown to be 
hypersensitive to DEB.  However, a possible involvement of this recombination repair 
pathway in the protection of cells against DEB-induced DNA damage remains to be explored 
using transgenic animals.  
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